Employees of Novartis Pharma K.K. (NPKK) transferred
some data from research centers to a Tokyo hospital when that data
should have been sent directly without first passing through
Novartis hands, according to a report by Japanese broadcaster NHK
that was picked up by the Wall Street Journal.
"NPKK is currently investigating the allegations," Novartis said in
The data was from a not yet fully enrolled 55-patient trial testing
the Novartis cancer drug Tasigna, the company said.
"Novartis Pharma K.K. is aware of the media report regarding a small
investigator-initiated clinical study ... conducted to assess side
effects in patients with chronic myelocytic leukemia," Novartis said
in a statement.
"NPKK has conducted employee trainings on proper protocol related to
investigator-initiated clinical studies and believes that any
involvement of our medical representatives in investigator-initiated
clinical studies is inappropriate."
[to top of second column]
The University of Tokyo Hospital said it was re-examining test
results it had received but had uncovered no evidence that Novartis
employees had manipulated any of the data during the transfers,
according to the Wall Street Journal report.
(Reporting by Bill Berkrot; editing by
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.